Filing Details
- Accession Number:
- 0001714899-22-000035
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-11 17:19:21
- Reporting Period:
- 2022-02-09
- Accepted Time:
- 2022-02-11 17:19:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1724310 | J. Ryan Watts | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-02-09 | 2,719 | $37.55 | 2,119,442 | No | 4 | S | Indirect | See footnote |
| Common Stock | Acquisiton | 2022-02-10 | 64,631 | $5.28 | 254,522 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2022-02-10 | 6,118 | $9.60 | 260,640 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote |
| No | 4 | M | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2022-02-10 | 64,631 | $0.00 | 64,631 | $5.28 |
| Common Stock | Stock Option (right to buy) | Disposition | 2022-02-10 | 6,118 | $0.00 | 6,118 | $9.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2027-03-07 | No | 4 | M | Direct | |
| 0 | 2027-08-21 | No | 4 | M | Direct |
Footnotes
- Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $37.51 to $37.745 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 8800 restricted stock units held by the Reporting Person.
- The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- Includes 189,891 restricted stock units.
- The shares subject to the option were fully vested and exercisable.
Billionaire Hedge Funds
